Tirzepatide significantly reduces cardiovascular death or worsening heart failure risk by 38% in patients with obesity-related HFpEF. The drug improves blood pressure, inflammation, and volume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback